Journal of Neuro-Oncology

, 89:113

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

  • Tyler Y. Kang
  • Tony Jin
  • Heinrich Elinzano
  • David Peereboom
Clinical-patient studies

Abstract

Recurrent high-grade gliomas are resistant to chemotherapy and have poor prognosis. The combination of irinotecan and bevacizumab has been reported to be an active regimen in the treatment of this disease. Herein we report our experience with this regimen with the objective of evaluating its efficacy and examining its safety profile. We performed a retrospective review of 27 patients with recurrent or progressive high-grade gliomas treated at the Cleveland Clinic Brain Tumor and Neuro-Oncology Center from 7/2005 through 10/2006. Patients with at least one prior chemotherapy regimen were included. Patients with prior irinotecan or bevacizumab were excluded. Outcomes were analyzed on an intention-to-treat basis and estimated by the Kaplan–Meier method. The median age of the group was 46 years and the median number of prior therapies was two. Eighteen of 27 patients have progressed, and 11 patients have died at time of analysis. Progression-free survival at 6 months is 46% and overall survival at 6 months is 84% with a median overall survival of 12.6 months. Of 12 patients with pretreatment radiographic evidence of intracranial hemorrhage, only one developed symptomatic progression of hemorrhage that required termination of therapy. Our experience suggests that the combination of irinotecan and bevacizumab improves the outcome in progressive high-grade gliomas when compared to historical results. While the rate of severe toxicities is consistent with prior reports and mandates careful selection of patients, asymptomatic, stable intracranial blood products or hemorrhage is likely not an absolute contraindication to therapy.

Keywords

Brain tumors Bevacizumab Intracranial hemorrhage Irinotecan Progressive glioma 

References

  1. 1.
    Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62(10):2152–2165PubMedCrossRefGoogle Scholar
  2. 2.
    Walker MD, Alexer E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333–343PubMedCrossRefGoogle Scholar
  3. 3.
    Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD et al (1999) Response and progression in recurrent malignant glioma. Neuro-oncology 1(4):282–288PubMedCrossRefGoogle Scholar
  4. 4.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578PubMedGoogle Scholar
  5. 5.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar
  6. 6.
    Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL et al (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39(3):187–191PubMedCrossRefGoogle Scholar
  7. 7.
    Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516–1525PubMedGoogle Scholar
  8. 8.
    Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology 8(2):189–193PubMedCrossRefGoogle Scholar
  9. 9.
    Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB et al (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55(2):91–100PubMedCrossRefGoogle Scholar
  10. 10.
    Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259PubMedCrossRefGoogle Scholar
  11. 11.
    Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma (Abstract). Neuro-oncology 7:369Google Scholar
  12. 12.
    Allkemper T, Tombach B, Schwindt W, Kugel H, Schilling M, Debus O et al (2004) Acute and subacute intracerebral hemorrhages: comparison of MR imaging at 1.5 and 3.0 T—initial experience. Radiology 232(3):874–881PubMedCrossRefGoogle Scholar
  13. 13.
    Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRefGoogle Scholar
  14. 14.
    Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779–1802PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Tyler Y. Kang
    • 1
    • 2
  • Tony Jin
    • 1
  • Heinrich Elinzano
    • 1
  • David Peereboom
    • 1
  1. 1.Cleveland Clinic Brain Tumor and Neuro-Oncology CenterClevelandUSA
  2. 2.Cleveland Clinic Taussig Cancer CenterClevelandUSA

Personalised recommendations